Corbus Pharmaceuticals Holdings, Inc.
LSE: 0SZI.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Yuval Cohen
- Employees
- 28
- Headquarters
- Norwood, United States
- IPO year
- 2018
- Market cap
- $137.0M
- Website
- https://www.corbuspharma.com
Loading 0SZI…
Loading profile data…Frequently asked questions about 0SZI
What does Corbus Pharmaceuticals Holdings, Inc. (0SZI.L) do?
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an...
Where does 0SZI.L trade?
Corbus Pharmaceuticals Holdings, Inc. (0SZI.L) trades on the London Stock Exchange.
What sector is 0SZI.L in?
Corbus Pharmaceuticals Holdings, Inc. (0SZI.L) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of Corbus Pharmaceuticals Holdings, Inc.?
Yuval Cohen is the chief executive officer of Corbus Pharmaceuticals Holdings, Inc. (0SZI.L).
Where is Corbus Pharmaceuticals Holdings, Inc. headquartered?
Corbus Pharmaceuticals Holdings, Inc. is headquartered in United States.
Does 0SZI.L pay a dividend?
Corbus Pharmaceuticals Holdings, Inc. (0SZI.L) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 0SZI.L go public?
Corbus Pharmaceuticals Holdings, Inc. (0SZI.L) completed its initial public offering in 2018.